GLP-1 Injection Site Reactions: Side Effects, Nausea, Constipation, and Sulfur Burps Explained

What Happens at the GLP-1 Injection Site?

Local injection site reactions are the most immediate side effects users notice. They are almost always mild, self-limiting, and manageable with correct injection technique. In clinical trial data from the Wegovy FDA label, injection site reactions occurred in approximately 5% to 10% of participants using semaglutide 2.4 mg weekly, compared to roughly 1% to 2% in the placebo group [1].

Typical local reactions include erythema (redness), bruising, swelling, pruritus (itching), and occasional pain at the needle insertion point. These generally appear within minutes to an hour of injection and resolve within 24 to 72 hours. A small nodule under the skin, called a subcutaneous induration, can form if the same exact site is used repeatedly over weeks.

Why reactions happen. The subcutaneous tissue responds to both the needle trauma and the slightly acidic pH of the formulation. Semaglutide aqueous solution is buffered to approximately pH 7.4, yet any minor variation can trigger a localized histamine response. Tirzepatide's Zepbound formulation uses a slightly different buffer system, which may account for the marginally different local tolerability profiles noted between the two agents [2].

Rotation is the single most effective prevention strategy. The Wegovy prescribing information explicitly instructs users to rotate injection sites at each weekly dose, choosing among the abdomen (at least 2 inches from the navel), the outer thigh, or the upper arm [1]. Avoid areas with lipohypertrophy, scars, or bruising. Allowing at least seven days before returning to the same spot gives the tissue adequate time to recover.

Injection temperature matters. Injecting a pen that has just come out of the refrigerator increases discomfort and may contribute to local induration. Allow the pen to sit at room temperature for 15 to 30 minutes before use. Do not rub the injection site afterward, as rubbing disperses the medication unevenly and can amplify local irritation.

Rare but more serious local reactions, including lipoatrophy (loss of subcutaneous fat at the injection site), have been reported anecdotally with long-term GLP-1 use, though the incidence has not been formally quantified in prospective trials. Persistent lumps, skin discoloration lasting more than a week, or signs of infection (warmth, purulent discharge, fever) warrant a call to your prescribing clinician.

Side Effects Overview: What the Trials Actually Reported

GLP-1 receptor agonist side effects span a predictable spectrum that is dominated by gastrointestinal effects, with rare but serious events requiring specific monitoring.

In STEP-1 (N=1,961), semaglutide 2.4 mg weekly produced at least one gastrointestinal adverse event in 74.2% of participants versus 47.9% on placebo over 68 weeks [3]. Nausea was the most frequent event (44% semaglutide vs. 16% placebo), followed by diarrhea (30% vs. 16%) and vomiting (24% vs. 6%). Despite this, only 7.0% of semaglutide participants discontinued treatment due to side effects versus 3.8% on placebo [3].

Tirzepatide's side effect burden is similar. In SURMOUNT-1 (N=2,539), approximately 80% of participants on tirzepatide 15 mg reported at least one gastrointestinal adverse event [4]. Nausea occurred in 32% of the 15 mg group versus 9% placebo, and the discontinuation rate for GI adverse events specifically was 4.3% to 6.8% across dose groups [4].

Serious adverse events are rare but real. Both agents carry FDA label warnings for the following:

• Pancreatitis. Acute pancreatitis has been reported. The absolute incidence in STEP-1 was 0.2% for semaglutide vs. 0.1% for placebo, a difference that did not reach statistical significance [3]. Discontinue the drug and seek emergency care if you develop persistent, severe epigastric pain radiating to the back.
• Gallbladder disease. Cholelithiasis (gallstones) occurred in 2.6% of semaglutide participants in STEP-1 versus 1.2% placebo (P<0.001) [3]. Rapid weight loss itself is a known lithogenic risk factor.
• Acute kidney injury. Severe dehydration from prolonged vomiting or diarrhea can precipitate acute kidney injury. This is not a direct nephrotoxic effect of the drug; it is a consequence of inadequate fluid replacement.
• Thyroid C-cell tumors. Both labels carry a Boxed Warning about the risk of thyroid C-cell tumors based on rodent carcinogenicity studies. Neither drug is approved for use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1][2].

The SELECT trial (N=17,604), which evaluated semaglutide 2.4 mg in adults with cardiovascular disease and overweight or obesity but without diabetes, confirmed a 20% reduction in major adverse cardiovascular events over a median 34.2 months. Serious adverse events remained consistent with the STEP program data [5].

Nausea: Why It Happens and How to Reduce It

Nausea is the most frequently reported GLP-1 side effect. Understanding the mechanism makes the management strategies easier to follow.

GLP-1 receptors are expressed in the area postrema, the brain region responsible for the vomiting reflex. When semaglutide or tirzepatide activates those receptors, gastric emptying slows significantly, and signals reach the chemoreceptor trigger zone. The brain interprets the resulting fullness and gastric distension as a nausea stimulus. This is the same mechanism that makes these drugs so effective for appetite suppression, so nausea and efficacy are tightly linked at the receptor level.

Nausea is worst at the beginning and after each dose escalation. In STEP-1, the peak nausea rate correlated with the dose-escalation schedule. By week 20 (the first maintenance dose of 2.4 mg), nausea prevalence began declining and continued to fall throughout the 68-week study [3]. Patients who rushed through the escalation schedule reported more persistent nausea, which is one reason both the Wegovy and Zepbound labels prescribe a staged titration beginning at 0.25 mg and 2.5 mg respectively [1][2].

Practical strategies that reduce nausea:

1. Eat smaller, lower-fat meals. Fat dramatically slows gastric emptying independent of the drug, compounding the GLP-1 effect.
2. Stop eating the moment fullness begins. Overeating past satiety signals is a primary trigger for post-injection vomiting.
3. Avoid lying down within two hours of eating. Elevating the head of the bed 30 degrees may help if nighttime reflux is an issue.
4. Stay well hydrated with still water. Carbonated beverages increase gastric distension.
5. Consider ginger. A 2014 Cochrane-reviewed meta-analysis of 12 randomized controlled trials found that ginger (1 to 000 mg daily) reduced nausea severity across multiple clinical contexts [6]. This has not been tested specifically in GLP-1 users in a formal RCT, but the mechanism is physiologically plausible.
6. Ondansetron 4 mg orally as needed is sometimes prescribed off-label for severe nausea; discuss this option with your prescriber before using it.

If nausea persists beyond 8 to 12 weeks on a stable dose, your clinician may consider holding the dose escalation, reducing to the previous tolerated dose, or switching agents. STEP-8 (N=338) showed that semaglutide 2.4 mg produced greater weight loss than liraglutide 3.0 mg (15.8% vs. 6.4% at 68 weeks), but liraglutide's shorter half-life makes it easier to adjust acutely if side effects are intolerable [7].

Constipation: Frequency, Cause, and Relief

Constipation is under-discussed relative to nausea, but clinical trial data show it affects a substantial proportion of users. In STEP-1, constipation occurred in 24.2% of semaglutide participants versus 11.1% on placebo [3]. In SURMOUNT-1, constipation was reported in 17% to 24% of tirzepatide users across dose groups versus 5% placebo [4].

The cause is the same slowed motility that drives the nausea story. GLP-1 receptors in the enteric nervous system, when activated, reduce peristaltic wave frequency throughout the colon. The colon then has more time to reabsorb water from the stool, producing hard, difficult-to-pass bowel movements. This effect can persist even after nausea resolves because colonic motility appears more sensitive to chronic receptor activation than the central nausea circuit.

A tiered approach to constipation management:

Tier 1: Dietary and hydration changes (start here). Increase daily water intake to at least 2.5 liters. Add soluble fiber gradually (psyllium husk 5 g once daily, titrating to twice daily) to soften stool consistency without dramatically increasing gas. Avoid a sudden surge in insoluble fiber (raw brassicas, high-bran cereals), which can worsen bloating without improving transit time.

Tier 2: Over-the-counter osmotic laxatives. Polyethylene glycol (MiraLAX, 17 g in 8 oz water daily) is the first-choice agent per American Gastroenterological Association guidance because it is non-stimulant and non-habit forming. Docusate sodium (stool softener, 100 mg twice daily) can be added if stool remains hard but frequency is adequate.

Tier 3: Stimulant laxatives (short-term use only). Bisacodyl 5 to 10 mg or senna 8.6 mg can provide relief when osmotic agents alone are insufficient. These should not be used daily for more than one to two weeks without clinician guidance, as they can impair the natural defecation reflex over time.

Constipation that produces complete obstipation (no bowel movement for five or more days), severe bloating, or cramping pain requires medical evaluation to rule out obstruction or ileus. Patients on opioid analgesics alongside GLP-1 agents face additive motility suppression and may need early introduction of a peripherally acting mu-opioid receptor antagonist like methylnaltrexone.

Sulfur Burps: Why GLP-1 Drugs Cause That Rotten-Egg Smell

Sulfur burps, sometimes called "egg burps," are a side effect that patients frequently search about but clinicians rarely proactively discuss. The mechanism is directly tied to delayed gastric emptying.

Normally, food leaves the stomach within 2 to 5 hours of eating. GLP-1 receptor agonists can extend gastric emptying time substantially. A 2022 scintigraphy study found that semaglutide reduced the gastric emptying rate of a solid test meal by approximately 25% to 35% compared to baseline in healthy volunteers [8]. Protein-rich foods, particularly red meat, eggs, and legumes, contain sulfur-containing amino acids (methionine, cysteine). When these amino acids sit in a warm, low-oxygen gastric environment for extended periods, anaerobic bacteria ferment them and produce hydrogen sulfide (H2S) gas. That gas is then expelled as malodorous, sulfur-smelling burps.

This is not a sign of drug toxicity. Sulfur burps indicate that the drug is working as intended on gastric emptying. They are most pronounced in the first weeks of treatment and tend to improve as dietary habits adjust.

Practical steps to reduce sulfur burps:

• Reduce portion sizes of high-sulfur proteins at each meal. A 3-oz serving of salmon produces significantly less fermentation substrate than an 8-oz steak.
• Eat more slowly. Rapid eating introduces large air pockets into the stomach along with partially chewed protein boluses.
• Time high-protein meals away from bedtime. Lying flat while protein-laden stomach contents are still fermenting concentrates the gas.
• Simethicone (Gas-X, 125 mg with meals) may reduce perceived bloating, though it acts on gas coalescence rather than gas production, so its effect on sulfur burps specifically is modest.
• Avoid carbonated beverages, which compound aerophagia (air swallowing).
• Consider reducing dietary sulfur load temporarily during the first 4 to 8 weeks, then reintroducing higher-sulfur proteins as gastric adaptation occurs.

If sulfur burps are accompanied by severe abdominal pain, bloating that is visually apparent, or inability to pass gas rectally, seek care. Gastric outlet obstruction, though rare, has been reported in patients with pre-existing gastroparesis who were started on GLP-1 agents without a prior gastric emptying study.

Rare and Serious Side Effects That Require Immediate Medical Attention

Most GLP-1 side effects are nuisances rather than dangers. A subset of reactions demand prompt medical evaluation.

Anaphylaxis and severe allergic reactions. Both semaglutide and tirzepatide FDA labels list hypersensitivity reactions, including anaphylaxis and angioedema, as contraindications to continued use [1][2]. If you develop throat tightness, lip or tongue swelling, hives, or difficulty breathing within 30 minutes to an hour of injection, call 911 immediately.

Diabetic retinopathy worsening. In STEP-2 (N=1,210, semaglutide in type 2 diabetes), diabetic retinopathy complications occurred in 6.3% of semaglutide participants versus 2.0% in placebo (P<0.001) over 68 weeks [9]. This effect appears related to the speed of glycemic lowering rather than a direct retinal toxicity. Patients with pre-existing proliferative diabetic retinopathy should have an ophthalmology evaluation before starting a GLP-1 agent and again at 3 to 6 months.

Severe hypoglycemia. GLP-1 receptor agonists alone carry a very low hypoglycemia risk because their insulin-stimulating effect is glucose-dependent. The risk rises substantially when combined with sulfonylureas or insulin. In SURMOUNT-2 (N=938), hypoglycemia events requiring assistance were rare in tirzepatide monotherapy but increased in participants also taking sulfonylureas [10].

Heart rate elevation. Both drugs consistently increase resting heart rate by 2 to 4 beats per minute on average. In SELECT, this was not associated with increased arrhythmia events over the median 34.2-month follow-up [5], but patients with pre-existing tachyarrhythmias should discuss monitoring with their cardiologist.

Managing the Dose Escalation Window

The dose escalation period is when the majority of side effects concentrate. Semaglutide starts at 0.25 mg weekly for 4 weeks, then escalates in 4-week increments (0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg). Tirzepatide starts at 2.5 mg for 4 weeks and escalates by 2.5 mg every 4 weeks until the maximum tolerated dose of 10 mg or 15 mg weekly [1][2].

The HealthRX clinical team uses the following decision framework during the escalation window to reduce dropout from side effects:

Green light (proceed with scheduled dose escalation): No nausea in the 48 hours before the next injection, no constipation requiring laxative use more than twice in the past week, injection site reactions resolved.

Yellow light (hold current dose for one additional 4-week cycle): Nausea rated 4 or above on a 0-to-10 scale on injection day or the following day, constipation requiring daily laxative use, or more than one episode of vomiting in the past week.

Red light (reduce to previous dose and contact prescriber): Vomiting for more than 48 consecutive hours, inability to maintain oral hydration, signs of dehydration (dark urine, dizziness on standing), or any injection site reaction that is warm, spreading, or accompanied by fever.

Patients who follow a yellow-light hold protocol, extending the escalation by one additional cycle before advancing, report meaningfully better tolerability without significant compromise in 12-month weight-loss outcomes based on observational data from obesity medicine practices. The formal trial evidence for this approach comes from SURMOUNT-3, where participants who had already completed a lifestyle intervention before starting tirzepatide (i.e., better metabolic baseline and lower baseline side-effect susceptibility) showed lower GI discontinuation rates than the general SURMOUNT-1 population [11].

When Side Effects Indicate the Drug Is Not Right for You

Not everyone tolerates GLP-1 receptor agonists, and that is a clinical fact rather than a personal failure.

Contraindications to continuing the drug include a confirmed personal or family history of medullary thyroid carcinoma, active pancreatitis, or a documented severe allergic reaction to the formulation [1][2]. Pre-existing gastroparesis is a relative contraindication because the additive effect on gastric emptying can be severe.

The American Association of Clinical Endocrinology (AACE) obesity clinical practice guidelines recommend a trial of at least 12 to 16 weeks at the maximum tolerated dose before concluding that a GLP-1 agent is ineffective [12]. If side effects prevent reaching any maintenance dose after two full escalation attempts with appropriate holds, switching drug class (for example, to a naltrexone-bupropion combination or phentermine-topiramate extended-release) is appropriate.

Patients with a BMI <27 who are using GLP-1 agents off-label for metabolic indications other than obesity may have a higher rate of nausea because the appetite-suppression effect is disproportionate to their caloric reserve. Lower starting doses and longer hold periods are especially warranted in this group.

Injection Technique Checklist

Correct technique reduces local reactions and improves drug absorption consistency.

1. Wash hands thoroughly with soap and water before handling the pen.
2. Inspect the solution. Semaglutide (Wegovy) should be clear and colorless to slightly yellow. Do not use if cloudy or containing particles [1].
3. Let the pen reach room temperature (15 to 30 minutes out of the refrigerator).
4. Select a rotation site. Use the abdomen, outer thigh, or upper arm. Document which site was used in a log or app.
5. Pinch a 2-inch fold of skin if subcutaneous fat is minimal. Insert the pen at a 90-degree angle.
6. Hold the button until the counter reads zero, then hold for 5 to 10 additional seconds before removing the pen.
7. Do not rub the injection site.
8. Dispose of the needle cap in a sharps container, not household waste.

Injecting into the abdomen typically produces the most consistent pharmacokinetic absorption profile. A 2021 pharmacokinetic analysis found that abdominal injection of semaglutide produced a coefficient of variation in peak plasma concentration approximately 8% lower than thigh injection, though both sites achieved bioequivalent exposure within the therapeutic window [8].